Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA

home / authors / ali-mcbride-pharmd-ms-bcop-fashp-fazpa

Articles

Dr. McBride on the Potential of Biosimilars in Oncology

Dr. McBride on the Potential of Biosimilars in Oncology

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA
December 5th 2019

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, discusses the potential utility of biosimilars in oncology.

Read More

Dr. McBride on the Regulatory Pathway for Biosimilars in Oncology

Dr. McBride on the Regulatory Pathway for Biosimilars in Oncology

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA
December 3rd 2019

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, clinical coordinator, Hematology/Oncology, The University of Arizona Cancer Center, clinical assistant professor, The University of Arizona College of Pharmacy, discusses the regulatory pathway for biosimilars in oncology.

Read More

Dr. McBride on the Emergence of Biosimilars in Oncology

Dr. McBride on the Emergence of Biosimilars in Oncology

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA
November 27th 2019

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, discusses factors that need to be taken into consideration as biosimilars emerge in oncology.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data